Montelucaste Accord (Montelukast)

Montelukast, the active ingredient in Montelucaste Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children, and is indicated for long‑term control of these respiratory and allergic conditions.

GNH USA supplies Montelucaste Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global healthcare providers, and ensures compliance with international quality standards.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and allergic responses.

Asthma (maintenance therapy): improves long‑term control of symptoms and reduces exacerbations. Allergic rhinitis (seasonal or perennial): alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache: mild to moderate head pain. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of sickness or urge to vomit. - Upper respiratory infection: symptoms such as sore throat, runny nose or cough. - Diarrhea: loose stools. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Liver enzyme elevation: abnormal liver function test results. - Blood dyscrasias: rare cases of neutropenia or thrombocytopenia.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

Assess asthma control: confirm that maintenance therapy is appropriate before initiating. Monitor for neuropsychiatric symptoms: observe patients for mood changes or suicidal thoughts. Use with caution in hepatic impairment: adjust therapy if liver disease is present. Avoid in patients with known hypersensitivity to montelukast or excipients. Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition may increase montelukast plasma levels, raising risk of adverse effects. - Phenobarbital: enzyme induction can lower montelukast concentrations, reducing therapeutic effect.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may modestly increase exposure; monitor for side effects. - Carbamazepine: enzyme induction may decrease montelukast levels; consider dose adjustment. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.